Actively Recruiting
A Study to Determine the Optimal Dose and Frequency of ALDP001 Nasal Spray in Adults With Seasonal Allergic Rhinitis Under Allergen Exposure
Led by Alixer Nexgen Therapeutics Limited · Updated on 2025-10-22
164
Participants Needed
1
Research Sites
23 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to evaluate the effectiveness and safety of ALDP001 Nasal Spray in treating seasonal allergic rhinitis, and to identify the optimal dosage and administration frequency for this formulation.
CONDITIONS
Official Title
A Study to Determine the Optimal Dose and Frequency of ALDP001 Nasal Spray in Adults With Seasonal Allergic Rhinitis Under Allergen Exposure
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of allergic rhinitis with seasonal symptoms lasting several months per year for more than 1 year
- Positive skin prick test to ragweed pollen with wheal diameter at least 3 mm larger than negative control within the past 12 months
- Healthy based on medical history, physical exam, vital signs, ECG, and lab tests as determined by an investigator
You will not qualify if you...
- Nasal abnormalities such as septal perforation, nasal polyps, sinusitis, or other malformations that may affect study results
- History of frequent nosebleeds
- Presence of rhinitis medicamentosa
- Current or chronic liver disease
- QTcF interval greater than 450 ms in males or greater than 470 ms in females
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cliantha Research
Mississauga, Ontario, Canada
Actively Recruiting
Research Team
A
Akhilesh Sharma
CONTACT
Y
Yogesh Rane
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here